Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Perjeta/Herceptin SC Combo Up for MHLW Panel Review on July 31
July 18, 2023
- Reflect Price and Wage Hikes in FY2024 Budget Guidelines, Lawmakers Urge
July 18, 2023
- Relief Claims OK’ed for 6 More Deaths Possibly Tied to COVID Jabs
July 18, 2023
- Japan Weighs Adoption of EMA Approach for Nitrosamine Impurities Risk Assessment
July 14, 2023
- Japan Govt to Stockpile Xofluza for 1.44 Million People
July 14, 2023
- Chuikyo OKs CEA Organization’s Reform Directions for FY2024
July 13, 2023
- Chuikyo Reps Want More Data from Industry to Review Launch Premiums
July 13, 2023
- Chuikyo Discusses Price Maintenance Premium, Focus Is on Company Criteria
July 13, 2023
- Chuikyo Split over Drug Lags and Losses, Rapid Introduction Evaluation System
July 13, 2023
- MHLW Certifies Antibiotics Supply Assurance Plans from Meiji, Fujifilm, Otsuka
July 12, 2023
- MHLW Panel OKs 172 More Health Damage Claims for COVID Vaccines
July 12, 2023
- MHLW Presents Plan to Expand Orphan Drug Designation by Clarifying Requirements
July 11, 2023
- Boost PMDA Manpower to Respond to Proposed Orphan Revamp: Panelists
July 11, 2023
- MHLW Proposes Simultaneous Preparation of Drug Development Plans for Adults and Children
July 11, 2023
- MHLW Pharma Regulation Panel Kicks Off, Agrees to Discuss Incentives to Develop Pediatric Drugs
July 11, 2023
- Label Expansions for Jakavi, Soliris Up for MHLW Panel Review on July 24
July 11, 2023
- PMDA US Office to Set Out Solution for Drug Lag, Loss: Agency Chief
July 10, 2023
- Amid High Turnover Rate, JPWA Presses for New System to Support Drug Prices
July 7, 2023
- Industry Stresses Stronger Price Support Rule to Ensure Stable Supplies
July 7, 2023
- Japan Appropriately Reviewing Alzheimer’s Med Lecanemab: Minister
July 7, 2023
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…